The DOI matches its Crossref record; 69 of the 77 references it cites were found in a registry or an index.
Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs
Abstract
Hypercholesterolemia is considered an important risk factor in coronary artery disease. Thus the possibility of controlling de novo synthesis of endogenous cholesterol, which is nearly two-thirds of total body cholesterol, represents an effective way of lowering plasma cholesterol levels. Statins, fungal secondary metabolites, selectively inhibit hydroxymethyl glutaryl-coenzyme A (HMG-CoA) reductase, the first enzyme in cholesterol biosynthesis. The mechanism involved in controlling plasma cholesterol levels is the reversible inhibition of HMG-CoA reductase by statins, related to the structural similarity of the acid form of the statins to HMG-CoA, the natural substrate of the enzymatic reaction. Currently there are five statins in clinical use. Lovastatin and pravastatin (mevastatin derived) are natural statins of fungal origin, while symvastatin is a semi-synthetic lovastatin derivative. Atorvastatin and fluvastatin are fully synthetic statins, derived from mevalonate and pyridine, respectively. In addition to the principal natural statins, several related compounds, monacolins and dihydromonacolins, isolated fungal intermediate metabolites, have also been characterized. All natural statins possess a common polyketide portion, a hydroxy-hexahydro naphthalene ring system, to which different side chains are linked. The biosynthetic pathway involved in statin production, starting from acetate units linked to each other in head-to-tail fashion to form polyketide chains, has been elucidated by both early biogenetic investigations and recent advances in gene studies. Natural statins can be obtained from different genera and species of filamentous fungi. Lovastatin is mainly produced by Aspergillus terreus strains, and mevastatin by Penicillium citrinum. Pravastatin can be obtained by the biotransformation of mevastatin by Streptomyces carbophilus and simvastatin by a semi-synthetic process, involving the chemical modification of the lovastatin side chain. The hypocholesterolemic effect of statins lies in the reduction of the very low-density lipoproteins (VLDL) and LDL involved in the translocation of cholesterol, and in the increase in the high-density lipoproteins (HDL), with a subsequent reduction of the LDL- to HDL-cholesterol ratio, the best predictor of atherogenic risk. The use of statins can lead to a reduction in coronary events related to hypercholesterolemia, but the relationship between benefit and risk, and any possible interaction with other drugs, must be taken into account.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Statins are competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the key enzyme which catalyzes the rate limiting step of sterols biosynthesis.24”
Citations
Cites
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644
Alberts, A. W., Chen, J., Kuron, G. W., Hunt, V. M., Huff, J. W., Hoffman, C., Rothrock, J. W., López, M., Joshua, H., Harris, E., et al. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.7.3957 · Cited by 1,630
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,216
Antiatherothrombotic Properties of Statins
Rosenson, R. S., & Tangney, C. (1998) · JAMA · doi:10.1001/jama.279.20.1643 · Cited by 954
ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogensis produced by Penicillium citrinum.
Endo, A., KURODA, M., & Tsujita, Y. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.1346 · Cited by 954
Endo, A., Kuroda, M., & Tanzawa, K. (1976) · FEBS Letters · doi:10.1016/0014-5793(76)80996-9 · Cited by 800
Monacolin K, a new hypocholesterolemic agent produced by a Monascus species.
ENDO, A. (1979) · The Journal of Antibiotics · doi:10.7164/antibiotics.32.852 · Cited by 670
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Hutchinson, C. R. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 656
The evolving role of statins in the management of atherosclerosis
Vaughan, C. J., Gotto, A. M., & Basson, C. T. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00525-2 · Cited by 573
Brown, M. S., Faust, J. R., Goldstein, J. L., Kaneko, I., & Endo, A. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38120-6 · Cited by 556
Pharmaceutically active secondary metabolites of microorganisms
Demain, A. L. (1999) · Applied Microbiology and Biotechnology · doi:10.1007/s002530051546 · Cited by 483
HMG-CoA Reductase Inhibitors and the Risk of Fractures
Meier, C. R. (2000) · JAMA · doi:10.1001/jama.283.24.3205 · Cited by 447
McTaggart, F., Buckett, L. K., Davidson, R. G., Holdgate, G. A., McCormick, A., Schneck, D. W., Smith, G., & Warwick, M. J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01454-0 · Cited by 413
Bakker-Arkema, R. G. (1996) · JAMA · doi:10.1001/jama.1996.03530260042029 · Cited by 406
Comparison of statins in hypertriglyceridemia
Stein, E. A., Lane, M., & Laskarzewski, P. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00041-1 · Cited by 386
Secondary metabolites of the fungusMonascus: A review
Jůzlová, P., Martı́nková, L., & Křen, V. (1996) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/bf01569999 · Cited by 386
Tsujita, Y., Kuroda, M., Shimada, Y., Tanzawa, K., ARAI, M., Kaneko, I., Tanaka, M., Masuda, H., Tarumi, C., Watanabe, Y., et al. (1986) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(86)90117-7 · Cited by 373
Discovery, biochemistry and biology of lovastatin
Alberts, A. W. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90002-1 · Cited by 358
Istvan, E. S., Palnitkar, M., Buchanan, S. K., & Deisenhofer, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.819 · Cited by 323
Endo, A. (1985) · Journal of Medicinal Chemistry · doi:10.1021/jm00382a001 · Cited by 286
Hoffman, W. F., Alberts, A. W., Anderson, P., Chen, J. S., Smith, R. L., & Willard, A. K. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00155a040 · Cited by 268
Auclair, K., Sutherland, A. J., Kennedy, J., Witter, D. J., van den Heever, J. P., Hutchinson, C. R., & Vederas, J. C. (2000) · Journal of the American Chemical Society · doi:10.1021/ja003216+ · Cited by 235
Endo, A. (1980) · The Journal of Antibiotics · doi:10.7164/antibiotics.33.334 · Cited by 233
Hendrickson, L. E., Davis, C. R., Roach, C., Nguyen, D. K., Aldrich, T. L., McAda, P. C., & Reeves, C. D. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80061-1 · Cited by 216
Tobert, J. A. (1987) · Circulation · doi:10.1161/01.cir.76.3.534 · Cited by 196
Current and future treatment of hyperlipidemia: the role of statins.
Farnier, M., & Davignon, J. (1998) · American Journal of Cardiology · doi:10.1016/s0002-9149(98)00423-8 · Cited by 196
Clinically relevant differences between the statins: implications for therapeutic selection
Chong, P. H., Seeger, J. D., & Franklin, C. M. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00870-1 · Cited by 195
The structure of the catalytic portion of human HMG-CoA reductase
Istvan, E. S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00134-7 · Cited by 144
Natural Statins and Stroke Risk
Furberg, C. D. (1999) · Circulation · doi:10.1161/01.cir.99.2.185 · Cited by 133
Moore, R. N., Bigam, G. E., Chan, J. K., Hogg, A. M., Nakashima, T. T., & Vederas, J. C. (1985) · Journal of the American Chemical Society · doi:10.1021/ja00298a046 · Cited by 121
SUTTER, J. D., Tavernier, R., Buyzere, M. D., Jordaens, L. J. L. M., & Backer, G. D. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00787-7 · Cited by 121
A chiral total synthesis of compactin
Hirama, M., & Uei, M. (1982) · Journal of the American Chemical Society · doi:10.1021/ja00379a037 · Cited by 109
Aspects of the biosynthesis of non-aromatic fungal polyketides by iterative polyketide synthases
Hutchinson, C. R., Kennedy, J., Park, C., Kendrew, S. G., Auclair, K., & Vederas, J. C. (2000) · Antonie van Leeuwenhoek · doi:10.1023/a:1010294330190 · Cited by 104
Monacolins J and L, new inhibitors of cholesterol biosynthesis produced by Monascus ruber.
Endo, A., Hasumi, K., & Negishi, S. (1985) · The Journal of Antibiotics · doi:10.7164/antibiotics.38.420 · Cited by 103
Purification and characterization of cytochrome P‐450sca from Streptomyces carbophilus
Matsuoka, T., Miyakoshi, S., Tanzawa, K., Nakahara, K., Hosobuchi, M., & Serizawa, N. (1989) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1989.tb15070.x · Cited by 102
Eisenberg, D. A. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00038-2 · Cited by 97
Microbial hydroxylation of ML-236B (compactin) and monacolin K (MB-530B)
Serizawa, N., Nakagawa, K., HAMANO, K., Tsujita, Y., Terahara, A., & Kuwano, H. (1983) · The Journal of Antibiotics · doi:10.7164/antibiotics.36.604 · Cited by 94
EFFECTS OF TRIPARANOL (MER-29) ON CHOLESTEROL BIOSYNTHESIS AND ON BLOOD STEROL LEVELS IN MAN*
Steinberg, D. H., Avigan, J., & Feigelson, E. B. (1961) · Journal of Clinical Investigation · doi:10.1172/jci104323 · Cited by 85
Dihydromonacolin L and monacolin X. new metabolites those inhibit cholesterol biosynthesis.
ENDO, A., Hasumi, K., Nakamura, T., KUNISHIMA, M., & Masuda, M. (1985) · The Journal of Antibiotics · doi:10.7164/antibiotics.38.321 · Cited by 84
Monacolin M, a new inhibitor of cholesterol biosynthesis.
ENDO, A., Komagata, D., & Shimada, H. (1986) · The Journal of Antibiotics · doi:10.7164/antibiotics.39.1670 · Cited by 80
Production of statins by filamentous fungi
Manzoni, M., Bergomi, S., Rollini, M., & Cavazzoni, V. (1999) · Biotechnology Letters · doi:10.1023/a:1005495714248 · Cited by 78
Self-citationCataracts produced by triparanol. (MER-29).
Kirby, T. J. (1967) · PubMed · Cited by 71
Levy, R. I., Aj, T., & Jm, F. (1993) · PubMed · Cited by 69
Gunde‐Cimerman, N., Friedrich, J. I., Cimerman, A., & Benički, N. (1993) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1993.tb06386.x · Cited by 63
Serizawa, N., SERIZAWA, S., Nakagawa, K., Furuya, K., OKAZAKI, T., & Terahara, A. (1983) · The Journal of Antibiotics · doi:10.7164/antibiotics.36.887 · Cited by 63
The synthesis of compactin (ML-236B) and monacolin K in fungi.
Endo, A., Hasumi, K., Yamada, A., SHIMODA, R., & Takeshima, H. (1986) · The Journal of Antibiotics · doi:10.7164/antibiotics.39.1609 · Cited by 62
Chan, J. K., Moore, R. N., Nakashima, T. T., & Vederas, J. C. (1983) · Journal of the American Chemical Society · doi:10.1021/ja00348a062 · Cited by 55
Novel approaches to lipid lowering: what is on the horizon?
Brown, W. V. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01452-7 · Cited by 51
Biosynthesis of ML-236B (compactin) and monacolin K.
Endo, A., NEGISHI, Y., Iwashita, T., Mizukawa, K., & Hirama, M. (1985) · The Journal of Antibiotics · doi:10.7164/antibiotics.38.444 · Cited by 44
Auclair, K., Kennedy, J., Hutchinson, C. R., & Vederas, J. C. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00290-6 · Cited by 42
Hosobuchi, M., Kurosawa, K., & Yoshikawa, H. (1993) · Biotechnology and Bioengineering · doi:10.1002/bit.260420705 · Cited by 41
OLSSON, A. G. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01455-2 · Cited by 41
Mevinolinic acid biosynthesis by Aspergillus terreus and its relationship to fatty acid biosynthesis
Greenspan, M. D., & Yudkovitz, J. B. (1985) · Journal of Bacteriology · doi:10.1128/jb.162.2.704-707.1985 · Cited by 37
ERIZAWA, N., Nakagawa, K., Tsujita, Y., Terahara, A., & UWANO, H. (1983) · The Journal of Antibiotics · doi:10.7164/antibiotics.36.608 · Cited by 37
Structure elucidation of the bioactive metabolites of ML-236B (mevastatin) isolated from dog urine.
Haruyama, H., Kuwano, H., Kinoshita, T., Terahara, A., Nishigaki, T., & Tamura, C. (1986) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.34.1459 · Cited by 35
Biosynthesis of monacolins: Conversion of monacolin J to monacolin K (mevinolin).
Kimura, K., Komagata, D., Murakawa, S., & ENDO, A. (1990) · The Journal of Antibiotics · doi:10.7164/antibiotics.43.1621 · Cited by 31
Statins as Cellular Antithrombotics
Fenton, J. W., & Shen, G. X. (1999) · Pathophysiology of Haemostasis and Thrombosis · doi:10.1159/000022496 · Cited by 30
Recent advances in the biosynthetic studies of lovastatin.
Sutherland, A. J., Auclair, K., & Vederas, J. C. (2001) · PubMed · Cited by 28
Komagata, D., Shimada, H., Murakawa, S., & ENDO, A. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.407 · Cited by 26
Differential metabolism of statins: importance in drug-drug interactions
Horsmans, Y. (1999) · Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) · Cited by 24
Fuzzy control in microbial production of ML-236B, a precursor of pravastatin sodium
Hosobuchi, M., Fukui, F., Suzuki, T., & Yoshikawa, H. (1993) · Journal of Fermentation and Bioengineering · doi:10.1016/0922-338x(93)90245-4 · Cited by 21
A new hydroxylase system in Actinomadura sp cells converting compactin to pravastatin
Peng, Y., & Demain, A. L. (1998) · Journal of Industrial Microbiology & Biotechnology · doi:10.1038/sj.jim.2900539 · Cited by 19
Hosobuchi, M., Fukui, F., Matsukawa, H., Suzuki, T., & Yoshikawa, H. (1993) · Journal of Fermentation and Bioengineering · doi:10.1016/0922-338x(93)90244-3 · Cited by 18
Hosobuchi, M., Ogawa, K., & Yoshikawa, H. (1993) · Journal of Fermentation and Bioengineering · doi:10.1016/0922-338x(93)90243-2 · Cited by 17
Biotransformation of Compactin to Pravastatin by Actinomadura sp. 2966.
Peng, Y., Yashphe, J., & Demain, A. L. (1997) · The Journal of Antibiotics · doi:10.7164/antibiotics.50.1032 · Cited by 17
Biosynthesis of mevinolin, a hypocholesterolemic fungal metabolite, in Aspergillus terreus.
Shiao, M. S., & Don, H. S. (1987) · PubMed · Cited by 17
New Microorganisms which Convert Compactin to Pravastatin.
Yashphe, J., Davis, J., Peng, Y., Bok, S. H., & Demain, A. L. (1997) · Actinomycetologica · doi:10.3209/saj.11_20 · Cited by 9
Serizawa, N., Hosobuchi, M., & Yoshikawa, H. (1997) · Drugs and the pharmaceutical sciences · doi:10.1201/b14856-27 · Cited by 7
ChemInform Abstract: TOTAL SYNTHESIS OF THE HYPOCHOLESTEROLEMIC AGENT COMPACTIN
Hsu, C. T., WANG, N. ‐., Latimer, L. H., & Sih, C. J. (1983) · ChemInform · doi:10.1002/chin.198321341 · Cited by 3
Flagged first, then by citations
8 of the 77 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
The production of fine chemicals by biotransformations
Straathof, A. J. J., Panke, S., & Schmid, A. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00360-9 · Cited by 684
Natural products and drug discovery
Ji, H., Li, X., & Zhang, H. (2009) · EMBO Reports · doi:10.1038/embor.2009.12 · Cited by 648
Importance of microbial natural products and the need to revitalize their discovery
Demain, A. L. (2013) · Journal of Industrial Microbiology & Biotechnology · doi:10.1007/s10295-013-1325-z · Cited by 431
Fermentation-enabled wellness foods: A fresh perspective
Xiang, H., Sun‐Waterhouse, D., Waterhouse, G. I. N., Cui, C., & Ruan, Z. (2019) · Food Science and Human Wellness · doi:10.1016/j.fshw.2019.08.003 · Cited by 377
Metabolic Engineering for the Production of Natural Products
Pickens, L. B., Tang, Y., & Chooi, Y. (2011) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-061010-114209 · Cited by 341
Metadata
- Authors
- Rollini, M. M.
- Venue
- Applied Microbiology and Biotechnology
- Published
- 2002-04-01
- Volume
- 58
- Issue
- 5
- Pages
- 555-564
- ISSN
- 0175-7598 (ISSN-L)
- 1432-0614
- OpenAlex
- W2156125238
- Cited by
- 410
- References
- 77
- Citations by year
- 2026: 8 · 2025: 15 · 2024: 15 · 2023: 22 · 2022: 22 · 2021: 12 · 2020: 32 · 2019: 23 · 2018: 16 · 2017: 13 · 2016: 22 · 2015: 20 · 2014: 16 · 2013: 23 · 2012: 29
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Applied Microbiology and Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Applied Microbiology and Biotechnology › Microbial Natural Products and Biosynthesis
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, fungal secondary metabolites, polyketide biosynthesis, HMG-CoA reductase inhibition, cholesterol biosynthesis, hypercholesterolemia, lovastatin, mevastatin, pravastatin, simvastatin, aspergillic acid, monacolins, Aspergillus terreus, Penicillium citrinum, biotransformation, cholesterol-lowering drugs
- MeSH terms
- Biotechnology, Fungi, Models, Chemical, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review